A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

NCT03265171 — No longer available, Prometic Biotherapeutics, Inc.
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia

RegistryNCT03265171
StatusNo longer available
Study typeExpanded access
SponsorPrometic Biotherapeutics, Inc. (Industry); collaborators: Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.
ConditionsHypoplasminogenemia
InterventionsPlasminogen (Human) (Biological)
Datesfirst posted 2017-08-29, last updated 2020-04-24

Related Papers Related Patents Related Grants Related Experts
All trials for Hypoplasminogenemia All trials of Plasminogen (Human)

-Summary

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

Expand all sections  ·  Collapse all

+Arms and interventions

  • Plasminogen (Human) (Biological)

+Eligibility

Sex: All, ages: 16 Months to any

Inclusion Criteria:

* Patient has provided informed consent.
* Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

Exclusion Criteria:

* Not applicable